—

Omega Fund Management, LLC

Q1 2026 13F Holdings

  • Location
    boston, MA
  • Num holdings

    10

  • Value ($000)

    $163,149

  • Date Filed
    05/15/2026
  • Form type
    13F-HR
  • CIK
    0001637359
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2026 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
---

Bicara Therapeutics Inc.

COMMON STOCK
055477103
$47.58M
29 %

2,392,150

N
NUVB

Nuvation Bio Inc.

COMMON STOCK CLASS A
67080N101
$34.67M
21 %

8,081,089

---

BridgeBio Oncology Therapeutics Inc.

COMMON STOCK
107924102
$29.44M
18 %

3,289,661

---

Kestra Med Technologies Ltd

COMMON STOCK
G52441105
$20.37M
13 %

1,022,149

---

Beta Bionics Inc.

COMMON STOCK
08659B102
$13.19M
8 %

1,316,183

E
ENGN

enGene Holdings Inc.

COMMON STOCK
29286M105
$5.97M
4 %

876,357

A
ALMS

Alumis Inc.

COMMON STOCK
022307102
$5.31M
3 %

241,255

S
SANA

Sana Biotechnology, Inc.

COMMON STOCK
799566104
$2.43M
2 %

843,750

---

ImageneBio, Inc.

COMMON STOCK
45175G207
$2.28M
1 %

455,361

R
REPL

Replimune Group

COMMON STOCK
76029N106
$1.91M
1 %

248,672

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 10